Theranexus (EPA:ALTHX) | Finanzwire

Basculer en Français

9821	Companies
197095	Keywords
128171	Articles
104822	Press releases

Home
Companies
Theranexus

PRESS RELEASE

published on 07/11/2024 at 18:45, 1 year 6 months ago

Theranexus publishes its cash position as of 30 June 2024 and presents an update on the progress of Batten-1
Biopharmaceutical company Theranexus announces implementation of new equity line to finance Phase III trial for Batten-1 drug in juvenile Batten disease. Update on Batten-1 program included

Biopharmaceutical Company Phase III Trial Theranexus Batten-1 Equity Line
BRIEF

published on 07/03/2024 at 07:35, 1 year 7 months ago

Theranexus, CRNL and CERMEP winners of the Auvergne-Rhône-Alpes “Research Pact 2024” project

Research Neurology Auvergne-Rhône-Alpes Theranexus Neuroimaging
PRESS RELEASE

published on 07/03/2024 at 07:30, 1 year 7 months ago

THERANEXUS, LYON NEUROSCIENCE RESEARCH CENTER AND CERMEP WIN THE "2024 RESEARCH PACT" PROJECT FOR THE AUVERGNE-RHÔNE-ALPES REGION
Theranexus, Lyon Neuroscience Research Center, and CERMEP win research pact project 'IMASO' in Auvergne-Rhône-Alpes Region for preclinical neuroimaging in rare neurological diseases

Theranexus Neurological Diseases Research Pact Auvergne-Rhône-Alpes Region Preclinical Neuroimaging
BRIEF

published on 06/06/2024 at 07:35, 1 year 8 months ago

Theranexus and BBDF Announce Positive Results at 18 Months for Batten-1 in Phase 1/2 Study

Theranexus Batten-1 BBDF Batten Disease Neurofilaments
PRESS RELEASE

published on 06/06/2024 at 07:30, 1 year 8 months ago

Theranexus and BBDF confirm positive 18-month results for Batten-1 in Phase I/II trial based on neurofilaments, a biomarker of neuronal death
Theranexus and BBDF confirm positive results in Phase I/II trial evaluating Batten-1 drug for CLN3 Batten disease after 18 months of treatment, showing decline in NfL biomarker levels and therapeutic potential

Theranexus Batten-1 BBDF CLN3 Batten Disease Neurofilament Light Chains
BRIEF

published on 05/02/2024 at 07:35, 1 year 9 months ago

Theranexus unveils its universal registration document for 2023

2023 Biopharmaceutical Universal Registration Document Theranexus Rare Neurological Diseases
BRIEF

published on 04/29/2024 at 18:25, 1 year 9 months ago

Theranexus Reports 2023 Full-Year Results and Details Recent Progress

2023 Financial Results Theranexus Rare Neurological Diseases PickASO Project Batten Disease
PRESS RELEASE

published on 04/29/2024 at 18:20, 1 year 9 months ago

THERANEXUS PUBLISHES ITS 2023 FULL-YEAR RESULTS AND PRESENTS ITS PROGRESS REPORT
Theranexus reports 2023 financial results, cash position, progress report, and the arrival of Christine Placet as CFO. Highlights include positive Batten-1 trial results and funding options for future trials

Financial Results Theranexus Rare Neurological Diseases Christine Placet Batten-1 Trial
BRIEF

published on 04/29/2024 at 18:05, 1 year 9 months ago

Theranexus announces its 2023 annual results and the progress of its projects

Biotechnology 2023 Financial Results Rare Diseases Theranexus Research Phase
BRIEF

published on 04/26/2024 at 18:05, 1 year 9 months ago

Theranexus releases voting rights and capital information for March 2024

Share Capital Voting Rights Biopharmaceutical Neurology Theranexus

Accesswire

Published on 02/07/2026 at 01:00, 1 day 5 hours ago

Green Bridge Metals Can Help Secure U.S. Production of Critical Mineral Titanium
Published on 02/06/2026 at 23:10, 1 day 7 hours ago

Topline Capital Management, LLC Announces Disposition of Shares of NamSys Inc.
Published on 02/06/2026 at 22:01, 1 day 8 hours ago

Totec Resources Announces Listing of Shares on the Frankfurt Stock Exchange and Adoption of Omnibus Incentive Plan
Published on 02/06/2026 at 15:30, 1 day 15 hours ago

Vulcan Minerals Inc. - Drilling Program Update for the Carbonear Zinc-Lead SEDEX project in Newfoundland
Published on 02/06/2026 at 13:30, 1 day 17 hours ago

Redwood AI Corp. (formerly Marshall Technologies Corp.) Announces Closing of IPO and Listing of Shares on the Canadian Securities Exchange

View all ACCESSWIRE

EQS Group

Published on 02/07/2026 at 21:00, 9 hours 41 minutes ago

Alibaba Group Debuts 'Wonder on Ice,' an Immersive AI Experience at Milan’s Sforza Castle for Milano Cortina 2026
Published on 02/07/2026 at 16:35, 14 hours 6 minutes ago

The Ministry of Finance and the International Monetary Fund to launch tomorrow the second edition of the AlUla Conference for Emerging Market Economies
Published on 02/07/2026 at 16:20, 14 hours 21 minutes ago

NOTICE OF SETTLEMENT APPROVAL HEARING - SHORT FORM - WAYLAND GROUP CORP., SCOTT LANGILLE, GERHARD MÜLLER, PAUL PATHAK, ERIC SILVER, MICHAEL STEIN, JOHN DOES 1-3, CANACCORD GENUITY CORP., AND RF SECURITIES CLEARING LP (FORMERLY KNOWN AS GMP SECU
Published on 02/06/2026 at 19:25, 1 day 11 hours ago

Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 02/06/2026 at 17:52, 1 day 12 hours ago

EQS-Adhoc: Avemio AG: Preparation of the filing for insolvency proceedings by Teltec AG, a subsidiary of Avemio AG, and potential effects on the going-concern assessment of Avemio AG

Les Echos

Published on 02/06/2026 at 18:22, 1 day 12 hours ago

Disclosure of Share Capital and Voting Rights as of January 31, 2026
Published on 02/06/2026 at 16:01, 1 day 14 hours ago

Notice of exercise of early redemption option of the subordinated note ISIN : FR0010093328
Published on 02/05/2026 at 19:24, 2 days 11 hours ago

Minutes of the Combined General Meeting
Published on 02/05/2026 at 18:24, 2 days 12 hours ago

LNA SANTE : 2025 annual sales
Published on 02/05/2026 at 18:06, 2 days 12 hours ago

Aéroports de Paris SA - Shares and voting rights as of 31 January 2026

View all LES ECHOS COMFI WIRE